Compression Therapy for Swelling Management Following Ankle Injury
Launched by NOVA SCOTIA HEALTH AUTHORITY · Jan 9, 2025
Trial Information
Current as of July 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying whether wearing a Bauerfeind ankle compression sleeve can help reduce swelling after an ankle injury or surgery. Swelling is a common issue that can occur after treatment, and managing it effectively is important to avoid complications and improve recovery. Currently, patients typically wear a walking boot after six weeks, which can lead to increased swelling. This study aims to compare the effects of using the compression sleeve alongside the walking boot to just using the boot alone to see if it helps patients recover better with less swelling and pain.
To participate in this trial, you need to be at least 18 years old and undergoing specific ankle surgeries or treatments at the Queen Elizabeth II Health Sciences Center. However, if you have complications with wound healing or certain health conditions, or if you can’t progress to a walking boot after six weeks, you may not be eligible. Participants can expect to have their swelling and pain monitored throughout the study, and the safety of the compression sleeve will also be evaluated. This trial is important as it could lead to better ways of managing swelling after ankle injuries or surgery, helping patients recover more smoothly.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients undergoing outpatient ankle, mid-foot or hindfoot arthrodesis, fracture surgery, or non-operative ankle fracture management at the Queen Elizabeth II Health Sciences Center.
- • Aged 18 or over
- Exclusion Criteria:
- • Patients undergoing other ankle procedures
- • Patients who have any signs of wound healing complications post-surgery
- • Patients who are unable to progress to walking boot and weight-bearing management at 6 weeks post operation/injury.
- • Patients with other co-morbidities that may create bias within the results (lymphedema, heart conditions etc.)
- • Patients who are unable to speak and read English, and/or in the opinion of the Principal Investigator are unable to provide fully informed consent.
About Nova Scotia Health Authority
The Nova Scotia Health Authority (NSHA) is a leading healthcare organization dedicated to enhancing the health and well-being of individuals and communities across Nova Scotia, Canada. As the largest provider of health services in the province, NSHA is committed to advancing clinical research and innovation through rigorous clinical trials that aim to improve patient care and outcomes. With a focus on collaboration, NSHA engages healthcare professionals, researchers, and patients to address pressing health challenges and contribute to the global body of medical knowledge. By fostering a culture of evidence-based practice and continual improvement, NSHA plays a pivotal role in shaping the future of healthcare delivery in the region.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Halifax, Nova Scotia, Canada
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported